BioNTech's Q4 results were hit by Pfizer's inventory writedo...
BioNTech's Q4 results were hit by Pfizer's inventory writedowns. Despite a drop in vaccine sales, it remains a leader in the COVID-19 vaccine market and is advancing in cancer treatments. Lower-than-expected earnings and revenue, along with fewer vaccine doses delivered, could hurt the stock.
BioNTech's Stock Sinks After Earnings Miss, as Inventory Writedowns Weigh
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment